1051899-83-2Relevant articles and documents
Discovery and Optimization of a Novel Series of Highly Selective JAK1 Kinase Inhibitors
Grimster, Neil P.,Anderson, Erica,Alimzhanov, Marat,Bebernitz, Geraldine,Bell, Kirsten,Chuaqui, Claudio,Deegan, Tracy,Ferguson, Andrew D.,Gero, Thomas,Harsch, Andreas,Huszar, Dennis,Kawatkar, Aarti,Kettle, Jason G.,Lyne, Paul,Read, Jon A.,Rivard Costa, Caroline,Ruston, Linette,Schroeder, Patricia,Shi, Jie,Su, Qibin,Throner, Scott,Toader, Dorin,Vasbinder, Melissa,Woessner, Richard,Wang, Haixia,Wu, Allan,Ye, Minwei,Zheng, Weijia,Zinda, Michael
supporting information, p. 5235 - 5244 (2018/06/11)
Janus kinases (JAKs) have been demonstrated to be critical in cytokine signaling and have thus been implicated in both cancer and inflammatory diseases. The JAK family consists of four highly homologous members: JAK1-3 and TYK2. The development of small-m
N' - (PHENYL) -N- (MORPHOLIN-4-YL-PYRIDIN-2-YL) -PYRIMIDINE-2, 4-DIAMINE DERIVATIVES AS EPHB4 KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE CONDITIONS
-
Page/Page column 58-59, (2008/12/08)
The invention concerns pyrimidine com pounds of Formula (I), or a pharmaceutically acceptable salt thereof where A1, A2, A3, R1, n, R2, R3, and R4 are as defined in the descripti